Department of Microbiology, University Hospital Virgen de las Nieves, Granada, Spain; Clinical Medicine and Public Health, Postgraduate programme, University of Granada, Granada, Spain
Auto-generated profile, based on publicly available information
Yannick Hoyos-Mallecot
Department of Microbiology, University Hospital Virgen de las Nieves, Granada, Spain; Clinical Medicine and Public Health, Postgraduate programme, University of Granada, Granada, Spain
Leishmaniasis is a clinically heterogeneous syndrome caused by intracellular protozoan parasites of the genus Leishmania. The clinical spectrum of leishmaniasis encompasses subclinical ( not apparent), localized (skin lesion), and disseminated (cutaneous, mucocutaneous, and visceral) infection. This spectrum of manifestations depends on the immune status of the host, on the parasite, and on immunoinflammatory responses. Visceral leishmaniasis causes high morbidity and mortality in the developing world. Reliable laboratory methods become mandatory for accurate diagnosis, especially in immunocompromised patients such as those infected with HIV. In this article, we review the current state of the diagnostic tools for leishmaniasis, especially the serological test.
1 September 2017 in Antimicrobial Agents and Chemotherapy
OXA-244 is a single-point-mutant derivative of OXA-48 displaying reduced carbapenemase activity. Here, we report the microbiological features of seven OXA-244-producing Escherichia coli isolates. Only one isolate grew on ChromID Carba Smart medium (bioMérieux), but six of the seven isolates grew on ChromID extended-spectrum-β-lactamase (ESBL) medium (bioMérieux), as they coproduced an ESBL and/or a plasmid-encoded cephalosporinase. The production of a carbapenemase was detected in 57.1%, 71.4%, 71.4%, and 100% of the E. coli isolates using the Carba NP test, the Rapidec Carba NP test (bioMérieux), a matrix-assisted laser desorption ionization–time of flight mass spectrometry (MALDI-TOF MS) hydrolysis assay (Bruker), and the OXA-48 K-SeT assay (Coris BioConcept), respectively. Our results indicate that OXA-244-producing E. coli isolates are difficult to detect, which may lead to their silent spread.
1 June 2017 in International Journal of Antimicrobial Agents
We have evaluated a matrix‐assisted laser desorption ionization–time of flight mass spectrometry (MALDI‐TOF MS) method for the identification of carbapenemases and for distinguishing metallo‐β‐lactamases (MBLs). A total of 49 noncarbapenemase‐producing and 14 carbapenemase‐producing Enterobacteriaceae and Pseudomonas aeruginosa clinical strains, previously characterized by PCR, were included in the study. With MALDI‐TOF MS, the presence of carbapenemases was confirmed by the detection of ertapenem hydrolysis (lost of molecular peaks: 476·5 Da, 498·5 Da, 520·5 Da and presence of degradation products) in the mixture of the bacteria with the antibiotic, and classification was achieved by selective inhibition of carbapenemase activity (the ertapenem molecular peak was maintained) with ethylenediaminetetraacetic acid (EDTA). We obtained a good concordance among the results of PCR and MALDI‐TOF MS. This method appears to be simple, fast and reliable for distinguishing in few hours different classes of carbapenemases, which can be very useful for epidemiological studies or to establish a specific antimicrobial therapy. Significance and Impact of the Study MALDI‐TOF mass spectrometry is increasingly present in microbiology laboratories due to its increasing use for bacterial identification. This study describes a method for detection of carbapenemase activity using MALDI‐TOF, which is similar to the reference method: the detection of imipenem hydrolysis using UV spectrometry.
1 July 2017 in Diagnostic Microbiology and Infectious Disease